Oral administration of therapeutic agent coupled to transporting agent

• US 20050208032A1
• Filed: 01/18/2005
• Published: 09/22/2005
• Est. Priority Date: 01/16/2004
• Status: Abandoned Application

• Current Assignee: NeoX, Inc.
• Original Assignee: NeoX, Inc.
• Inventors: Vargas, Gomez, Hortelano, Gonzalo
• Application Number:
  US11/039,679
• Publication Number:
  US 20050208032A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity

Abstract

The present invention is directed toward a composition for widespread distribution, systemic expression and sustained delivery of a therapeutic or transdifferentiating agent and to a process for administration of said agent via a natural gastrointestinal pathway. More particularly, the invention discloses a composition for the administration of oral gene therapy and a process for its production and use.

Claims

1. A process for production of insulin in a diabetic mammal by provision of a transdifferentiating moiety including at least one homeogene operably linked to a promoter, which induces transdifferentiation of host cells in vivo to instigate the formation of insulin producing cells comprising:

providing at least one transporting agent effective for enabling widespread distribution, systemic expression and sustained delivery of said transdifferentiating moiety via said natural gastrointestinal pathway;

forming a distributable moiety by coupling said transporting agent, at least one compound effective for protecting said transdifferentiating moiety within said natural gastrointestinal pathway, and said transdifferentiating moiety in a manner effective to enable widespread distribution, systemic delivery and sustained expression upon intracellular absorption via said natural gastrointestinal pathway;

orally administering said distributable moiety by way of a natural gastrointestinal pathway;

transporting said distributable moiety in vivo via said natural gastrointestinal pathway, whereby said transdifferentiating moiety is included within essentially all cells of said subject; and

transdifferentiating host cells to instigate the formation of insulin producing cells,

whereby insulin is produced by said mammal in amounts effective to achieve controlled glycemia.

2. The process in accordance with claim 1 wherein said transporting agent is a polypeptide.

3. The process in accordance with claim 1 wherein said transporting agent is a compound containing an amine group and is constructed and arranged to couple with said transdifferentiating moiety to enable widespread distribution, systemic expression and sustained delivery of said therapeutic.

4. The process in accordance with claim 1 wherein said compound effective for protecting said transdifferentiating moiety is selected from the group consisting of chitosan, collagen, and alginate.

5. The process in accordance with claim 1 wherein said coupling is via electrostatic binding.

6. The process in accordance with claim 1 wherein said promoter is selected from the group consisting of tissue specific and ubiquitous promoters.

7. The process in accordance with claim 1 wherein said homeogene is PDX-1 operably linked to a β

-actin promoter.

8. A process for production of insulin in a diabetic mammal by provision of an insulin producing moiety containing at least one insulin producing DNA linked to a promoter, which induces in vivo formation of insulin comprising:

providing at least one transporting agent effective for enabling widespread distribution, systemic expression and sustained delivery of said insulin producing moiety via said natural gastrointestinal pathway;

forming a distributable moiety by coupling said transporting agent, at least one compound effective for protecting said insulin producing moiety within said natural gastrointestinal pathway, and said insulin producing moiety in a manner effective to enable widespread distribution, systemic delivery and sustained expression upon intracellular absorption via said natural gastrointestinal pathway;

orally administering said distributable moiety by way of a natural gastrointestinal pathway; and

transporting said distributable moiety in vivo via said natural gastrointestinal pathway, wherein said insulin producing moiety is included within essentially all cells of said subject;

whereby insulin is encoded by said mammal in amounts effective to achieve controlled glycemia.

9. The process in accordance with claim 8 wherein said transporting agent is a polypeptide.

10. The process in accordance with claim 8 wherein said transporting agent is a compound containing an amine group and is constructed and arranged to couple with said insulin producing moiety to enable widespread distribution, systemic expression and sustained delivery of said therapeutic.

11. The process in accordance with claim 8 wherein said compound effective for protecting said insulin producing moiety is selected from the group consisting of chitosan, collagen, and alginate.

12. The process in accordance with claim 8 wherein said transporting agent is a polypeptide.

13. The process in accordance with claim 8 wherein said coupling is via electrostatic binding.

14. The process in accordance with claim 8 wherein said promoter is selected from the group consisting of tissue specific and ubiquitous promoters.

15. The process in accordance with claim 8 wherein said insulin producing DNA is operably linked to a β

-actin promoter.

16. A process for production of a therapeutic agent in a mammal in need thereof by provision of a therapeutic agent producing moiety containing at least one therapeutic agent producing DNA linked to a promoter, which induces in vivo formation of said therapeutic agent comprising:

providing at least one transporting agent effective for enabling widespread distribution, systemic expression and sustained delivery of said therapeutic agent producing moiety via said natural gastrointestinal pathway;

forming a distributable moiety by coupling said transporting agent, at least one compound effective for protecting said therapeutic agent producing moiety within said natural gastrointestinal pathway, and said therapeutic agent producing moiety in a manner effective to enable widespread distribution, systemic delivery and sustained expression upon intracellular absorption via said natural gastrointestinal pathway;

orally administering said distributable moiety by way of a natural gastrointestinal pathway; and

transporting said distributable moiety in vivo via said natural gastrointestinal pathway, wherein said therapeutic agent producing moiety is included within essentially all cells of said subject;

whereby said therapeutic agent is encoded by said mammal in amounts effective to ameliorate a particular physiological condition.

17. The process in accordance with claim 16 wherein said transporting agent is a polypeptide.

18. The process in accordance with claim 16 wherein said transporting agent is a compound containing an amine group and is constructed and arranged to couple with said therapeutic agent producing moiety to enable widespread distribution, systemic expression and sustained delivery of said therapeutic agent.

19. The process in accordance with claim 16 wherein said compound effective for protecting said therapeutic agent producing moiety is selected from the group consisting of chitosan, collagen, and alginate.

20. The process in accordance with claim 16 wherein said coupling is via electrostatic binding.

21. The process in accordance with claim 16 wherein said promoter is selected from the group consisting of tissue specific and ubiquitous promoters.

22. The process in accordance with claim 16 wherein said therapeutic agent producing DNA is operably linked to a β

-actin promoter.

23. The process in accordance with claim 16 wherein said therapeutic agent is Factor VIII.

24. The process in accordance with claim 16 wherein said therapeutic agent is Factor IX.

25. The process in accordance with claim 16 wherein said therapeutic agent is human growth factor.

26. The process in accordance with claim 16 wherein said therapeutic agent is an antibody.

27. The process in accordance with claim 16 wherein said therapeutic agent is human growth hormone.

28. The process in accordance with claim 16 wherein said therapeutic agent is a protein selected from the group consisting of hematopoetic factors, colony stimulating factors, anti-obesity factors, growth factors, trophic factors, and antiinflammatory factors.

29. The process in accordance with claim 16 wherein said therapeutic agent is a protein selected from the group consisting of leptin, G-CSF, SCF, BDNF, GDNF, NT3, GM-CSF, IL-Ira, IL2, TNF-bp, MGDF, OPG, interferons, erythropoietin, KGF and analogs or derivatives thereof.